Current use of aflibercept 8 mg (eylea HD) in retinal diseases
Archives of Ophthalmological Research · 2024
DOI: 10.51271/aor-0003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Ophthalmological Research, 2024. Verfasst von Mehmet Çıtırık.
Abstract (Originalsprache)
Aflibercept 8 mg (Eylea HD) has emerged as a pivotal agent in the treatment of retinal diseases and has begun to showcase its efficacy and innovation in the field of ophthalmology. This article delves into the current use of aflibercept 8 mg, exploring its applications, mechanisms of action, and impact on the treatment landscape for various retinal conditions. This review provides an overview of recent clinical studies and highlights the key findings and advancements associated with the use of 8 mg aflibercept.
Zitieren
APA
Çıtırık, M. (2024). Current use of aflibercept 8 mg (eylea HD) in retinal diseases. Archives of Ophthalmological Research. https://doi.org/10.51271/aor-0003
Vancouver
Çıtırık M. Current use of aflibercept 8 mg (eylea HD) in retinal diseases. Archives of Ophthalmological Research. 2024. doi:10.51271/aor-0003
BibTeX
@article{trk2024,
author = {Çıtırık, Mehmet},
title = {Current use of aflibercept 8 mg (eylea HD) in retinal diseases},
journal = {Archives of Ophthalmological Research},
year = {2024},
doi = {10.51271/aor-0003}
}
EUVIMED